Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Nailed it - B. Riley Talk

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jan 21, 2021 9:12am

127 Views

Post# 32343255

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nailed it - B. Riley Talk

FWIW here's the 2nd investigator, another doc with a special interest in Ph1 trials, Istill can't work out the 3rd.
https://bio.cedars-sinai.org/mitam/index.html?_ga=2.246328708.1044119009.1611214605-356506799.1611214605

SPCEO1 wrote: Feel free to try to sort out what he said but I will say again that it is my impression that we will hear good news early if there is good news. That impression comes from previous conversations not from today's comments. I was told that revealing good info is the norm in open label cancer phase I trials.

scarlet1967 wrote: Ok if you say so I guess I need hearing aide

jfm1330 wrote: Soory. What you wrote is not word for word what he said. Be serious. And before all that he said: "when it comes down to the catalysts in our business in the next couple of months". So the reality is that he did not say he would report efficacy data as soon as they have it or before the end of the phase I. He said they would use early efficacy data to ask the FDA to speed up the development process. That's what he said.

scarlet1967 wrote: I was listening and writing my previous post word by word but let's move on.